​

Soleno Therapeutics Stock (NASDAQ:SLNO)

ForecastRevenueOwnershipFinancialsChart
Soleno Therapeutics by TradingView

Previous Close

$45.20

52W Range

$35.70 - $60.92

50D Avg

$53.01

200D Avg

$47.13

Market Cap

$1.95B

Avg Vol (3M)

$681.96K

Beta

-1.44

Div Yield

-

SLNO Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

33

IPO Date

Nov 13, 2014

Website

SLNO Performance

SLNO Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-38.67M$-24.40M$-31.53M
Net Income$-38.99M$-20.32M$-29.56M
EBITDA$-36.71M$-25.85M$-31.54M
Basic EPS$-2.36$-2.42$-5.56
Diluted EPS$-2.36$-2.42$-5.56

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
DAWNDay One Biopharmaceuticals, Inc.
BOLTBolt Biotherapeutics, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
PULMPulmatrix, Inc.
BPTHBio-Path Holdings, Inc.
CAPRCapricor Therapeutics, Inc.
ANNXAnnexon, Inc.
ABOSAcumen Pharmaceuticals, Inc.
BNTCBenitec Biopharma Inc.
ALRNAileron Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
MBRXMoleculin Biotech, Inc.
LYRALyra Therapeutics, Inc.